These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 19487951

  • 1. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study.
    Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M.
    J Acquir Immune Defic Syndr; 2009 Aug 01; 51(4):367-73. PubMed ID: 19487951
    [Abstract] [Full Text] [Related]

  • 2. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM, EASIER ANRS 138 study group.
    Clin Infect Dis; 2009 Oct 15; 49(8):1259-67. PubMed ID: 19757993
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.
    Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR.
    J Clin Virol; 2009 Dec 15; 46(4):305-8. PubMed ID: 19819183
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, TORO 1 Study Group.
    N Engl J Med; 2003 May 29; 348(22):2175-85. PubMed ID: 12637625
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
    Santos JR, Llibre JM, Ferrer E, Domingo P, Imaz A, Moltó J, Martin-Iguacel R, Caum C, Podzamczer D, Clotet B.
    HIV Clin Trials; 2009 May 29; 10(6):432-8. PubMed ID: 20133273
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
    Harris M, Larsen G, Montaner JS.
    AIDS; 2008 Jun 19; 22(10):1224-6. PubMed ID: 18525270
    [Abstract] [Full Text] [Related]

  • 11. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.
    Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, De Castro N, Caron F, Braun J, Molina JM, ANRS 138 EASIER Study Group.
    J Infect Dis; 2013 Sep 19; 208(6):892-7. PubMed ID: 23801606
    [Abstract] [Full Text] [Related]

  • 12. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP, Guimarães ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, Morgado MG.
    J Med Virol; 2012 Dec 19; 84(12):1869-75. PubMed ID: 23080489
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
    Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP.
    J Acquir Immune Defic Syndr; 2005 Dec 01; 40(4):404-12. PubMed ID: 16280694
    [Abstract] [Full Text] [Related]

  • 15. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
    Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM.
    AIDS; 2003 Mar 28; 17(5):691-8. PubMed ID: 12646792
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, Guerin C, Spiridon G, Salmon D, Guillevin L, Lebon P, Launay O.
    J Med Virol; 2006 Oct 28; 78(10):1312-7. PubMed ID: 16927284
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.